Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults

• Naveen Garg,

  Roles Investigation, Writing – review & editing

  Affiliation Centricity Research-Montreal, Point-Claire, Québec, Canada

  ⨯
• Guy Tellier,

  Roles Investigation, Writing – review & editing

  Affiliation Centricity Research-Mirabel, Mirabel, Québec, Canada

  ⨯
• Noah Vale,

  Roles Investigation, Writing – review & editing

  Affiliation Centricity Research-Toronto, Toronto, Ontario, Canada

  ⨯
• Jon Kluge,

  Roles Data curation, Project administration, Supervision, Writing – review & editing

  Affiliation Research and Development, Vaxess Technologies, Cambridge, Massachusetts, United States of America

  https://orcid.org/0000-0003-1119-0973

  ⨯
• Jonathan L. Portman,

  Roles Data curation, Writing – review & editing

  Affiliation Research and Development, Vaxess Technologies, Cambridge, Massachusetts, United States of America

  https://orcid.org/0009-0007-2075-0051

  ⨯
• Anna Markowska,

  Roles Data curation, Writing – review & editing

  Affiliation Research and Development, Vaxess Technologies, Cambridge, Massachusetts, United States of America

  ⨯
• Lynda Tussey

  Roles Conceptualization, Formal analysis, Project administration, Writing – original draft, Writing – review & editing

  * E-mail: lynda@vaxess.com

  Affiliation Development and MAP Production, Vaxess Technologies, Woburn, Massachusetts, United States of America

  https://orcid.org/0000-0002-7015-7295

  ⨯